Key facts
- It has raised $10.8M; the latest was Grant ($1.2M) in Jun 2025.
- Notable investors include Innovate UK, Mercia Ventures, Meltwind Advisory, IQ Capital Partners, Illumina Ventures — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Tagomics
- ·The full record, as it builds
Funding rounds
No funding rounds for Tagomics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Tagomics
Developer of epigenetic-based chemicals designed for throughput and cost-effective epigenetic biomarker discovery. The company specializes in epigenetic chemical modifications, which provide DNA a second layer of information, in addition to the genetic code, which is more dynamic and sensitive to lifestyle factors, the environment, and disease, enabling patients with biological markers, also known as biomarkers, for early detection colorectal and other common cancers.
- Sector
- Healthcare
- HQ
- Cambridge, United Kingdom
- Founded
- 2020
- Employees
- 16
- Website
- tagomics.com/
- Ownership
- Privately Held (backing)
Tagomics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Tagomics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Tagomics in its N-PORT filings yet. We sweep new filings monthly.